HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
遺伝子病制御研究所  >
雑誌発表論文等  >

Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S

フルテキスト
HumCell29_58.pdf946.85 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/64955

タイトル: Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S
著者: Abe, Hirotake 著作を一覧する
Wada, Haruka 著作を一覧する
Baghdadi, Muhammad 著作を一覧する
Nakanishi, Sayaka 著作を一覧する
Usui, Yuu 著作を一覧する
Tsuchikawa, Takahiro 著作を一覧する
Shichinohe, Toshiaki 著作を一覧する
Hirano, Satoshi 著作を一覧する
Seino, Ken-ichiro 著作を一覧する
キーワード: Breast cancer
4T1
Immunogenicity
Transformation
発行日: 2016年 4月
出版者: Springer
誌名: Human cell
巻: 29
号: 2
開始ページ: 58
終了ページ: 66
出版社 DOI: 10.1007/s13577-015-0127-1
抄録: Cancer vaccines serve as a promising clinical immunotherapeutic strategy that help to trigger an effective and specific antitumor immune response compared to conventional therapies. However, poor immunogenicity of tumor cells remains a major obstacle for clinical application, and developing new methods to modify the immunogenicity of tumor cells may help to improve the clinical outcome of cancer vaccines. 4T1 mouse breast cancer cell line has been known as poorly immunogenic and highly metastatic cell line. Using this model, we identified a sub cell line of 4T1-designated as 4T1-Sapporo (4T1-S)-which shows immunogenic properties when used as a vaccine against the same line. In 4T1-S-vaccinated mice, subcutaneous injection of 4T1-S resulted in an antitumor inflammatory response represented by significant enlargement of draining lymph nodes, accompanied with increased frequencies of activated CD8 T cells and a subpopulation of myeloid cells. Additionally, 4T1-S vaccine was ineffective to induce tumor rejection in nude mice, which importantly indicate that 4T1-S vaccine rely on T cell response to induce tumor rejection. Further analysis to identify mechanisms that control tumor immunogenicity in this model may help to develop new methods for improving the efficacies of clinical cancer vaccines.
Rights: The final publication is available at link.springer.com
資料タイプ: article (author version)
URI: http://hdl.handle.net/2115/64955
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 清野 研一郎

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学